Thread by @Biotech2k1

Looking at my AI Based Drug Development companies:

I am really happy with how this space is shaping up. I got 4 really good companies and the ability to circle the wagons around my favorite 3 if I need the cash in this down market. If triage is needed.

I have:

$SDGR = 3.34%
$RLAY = 2.76%
$RXRX = 1.38%
$EXAI = 1.38%

Total 8.96% of my portfolio.

Most of these positions are recent additions as so its mostly profitable. I did start buying $SDGR too soon. I could have waited longer but my DCA is still only $52 so its not that bad.

I think $SDGR is the really cheap one here at it has over $100 million in annual software sales that continues to grow and fund the majority of clinical development. They have a lot of great program targets.

I think $RLAY has the most clinical data with their early safety data in FGFR2 and PI3Ka. I think this is my favorite on the science as its doing some very awesome work to go after very challenging pathways in a safe way.

I have only just started a position in $RXRX with their use of robotic labs to run millions of test every week. The data they collect can be used to develop new drugs. They have an interesting pipeline. I just wish they had more data available from the phase 1 readouts.

I just recently got into $EXAI, and its quickly becoming one of my favorites. They have 2 programs. The first takes a single cell genomic profile and uses it to develop more effective cancer treatments to improve patient outcomes. The rest is developing new drugs.

This theme is one of my most exciting spaces for the next decade. The cost of developing new drugs is over $1 billion while the failure rate reaches 90%. The ability of machine learning and AI can dramatically help reduce costs and increase success.

Even if these changes are incremental as companies build out databases and software. I am sure there are many other companies in this space, but these are the 4 that I think stood out as best of breed to me.